QUANTUMDX-GROUP-LTD
3.2.2021 08:02:08 CET | Business Wire | Press release
QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announces its sensitive SARS-CoV-2 assay for laboratory use has been validated by NHS Test and Trace.
Key conclusions from the report verify QuantuMDx’s performance claims, confirming that the test has a Limit of Detection of less than 500 copies/ml, clinical sensitivity of 98.9% and clinical specificity of 99.1%, making it one of the most sensitive tests on the market. Furthermore, its performance fulfils the requirements of the MHRA’s Target Product Profile (TPP) for Laboratory-Based SARS-CoV-2 Viral Detection tests, essential for NHS Test & Trace’s validation process.
QuantuMDx’s SARS-CoV-2 assay, which delivers a result in approximately 70 minutes, following preparation and extraction of RNA is a real-time reverse transcriptase PCR (rtRT-PCR) test that has been developed using advanced bioinformatics to maximise performance. The assay has been designed with the most up-to-date sequence information available to ensure 100% coverage of all known SARS-CoV-2 sequences. This involves in silico analysis against The GISAID database at least fortnightly, or whenever new variants of concern are identified. The sensitive test targets three unique SARS-CoV-2 specific genomic loci; the S and N genes and the Orf1ab region. The assay can run on multiple open real-time PCR platforms, both high and low throughput. Furthermore, the assay reagents are lyophilised in a single vial, eliminating multiple pipetting steps, enabling convenient shipping and longer shelf-life.
Jonathan O’Halloran, Co-founder and Chief Executive Officer of QuantuMDx said: “We are pleased to see the publication of this report which confirms our test to be a sensitive and specific laboratory assay and underlines the quality of our science and development process. The progress that has been made with diagnostics, testing, and the emergence of an approved vaccine this year, is incredible. Despite this, however, we must not rest and must continue to fight this pandemic.”
QuantuMDx is also independently validating the use of the test without the need for RNA extraction, running the RT-PCR test directly from swabs. Furthermore, the company is validating the test for use with additional specimen types, including saliva.
In addition to having developed a SARS-CoV-2 test for laboratories, QuantuMDx continues preparations for scale- up and manufacture of its Q-POC™ rapid point-of-care testing device which would allow the sensitivity of molecular testing to move beyond the laboratory. The company is currently translating its SARS-CoV-2 detection assay to the Q-POC™ platform, as a respiratory panel for the detection and differentiation of SARS-SoV-2, Influenza A & B. Using swab samples, a Q-POC™ test could provide a result in approximately 30 minutes, at the point-of-need.
About QuantuMDx
QuantuMDx Group is an ambitious company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202006102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom